- Home
- MGNX vs ODV Comparison
MGNX vs ODV Comparison
Compare MGNX & ODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- ODV
- Stock Information
- Founded
- MGNX 2000
- ODV 2005
- Country
- MGNX United States
- ODV Canada
- Employees
- MGNX N/A
- ODV N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- ODV Precious Metals
- Sector
- MGNX Health Care
- ODV Basic Materials
- Exchange
- MGNX Nasdaq
- ODV Nasdaq
- Market Cap
- MGNX 202.7M
- ODV 239.0M
- IPO Year
- MGNX 2013
- ODV N/A
- Fundamental
- Price
- MGNX $2.86
- ODV $1.54
- Analyst Decision
- MGNX Hold
- ODV
- Analyst Count
- MGNX 10
- ODV 0
- Target Price
- MGNX $7.17
- ODV N/A
- AVG Volume (30 Days)
- MGNX 642.4K
- ODV 131.8K
- Earning Date
- MGNX 03-06-2025
- ODV 03-28-2025
- Dividend Yield
- MGNX N/A
- ODV N/A
- EPS Growth
- MGNX N/A
- ODV N/A
- EPS
- MGNX N/A
- ODV N/A
- Revenue
- MGNX $141,329,000.00
- ODV $8,487,361.00
- Revenue This Year
- MGNX $174.73
- ODV N/A
- Revenue Next Year
- MGNX N/A
- ODV $479.40
- P/E Ratio
- MGNX N/A
- ODV N/A
- Revenue Growth
- MGNX 16.68
- ODV N/A
- 52 Week Low
- MGNX $2.79
- ODV $1.34
- 52 Week High
- MGNX $21.88
- ODV $2.75
- Technical
- Relative Strength Index (RSI)
- MGNX 34.55
- ODV 42.26
- Support Level
- MGNX $2.93
- ODV $1.48
- Resistance Level
- MGNX $3.16
- ODV $1.68
- Average True Range (ATR)
- MGNX 0.18
- ODV 0.07
- MACD
- MGNX -0.02
- ODV 0.00
- Stochastic Oscillator
- MGNX 1.90
- ODV 35.29
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation and development activities of its projects.